495 related articles for article (PubMed ID: 16471901)
41. Epigallocatechin gallate is a slow-tight binding inhibitor of enoyl-ACP reductase from Plasmodium falciparum.
Banerjee T; Sharma SK; Surolia N; Surolia A
Biochem Biophys Res Commun; 2008 Dec; 377(4):1238-42. PubMed ID: 18992222
[TBL] [Abstract][Full Text] [Related]
42. A natural theaflavins preparation inhibits HIV-1 infection by targeting the entry step: potential applications for preventing HIV-1 infection.
Yang J; Li L; Tan S; Jin H; Qiu J; Mao Q; Li R; Xia C; Jiang ZH; Jiang S; Liu S
Fitoterapia; 2012 Mar; 83(2):348-55. PubMed ID: 22155187
[TBL] [Abstract][Full Text] [Related]
43. Structure-activity relationships of synthetic analogs of (-)-epigallocatechin-3-gallate as proteasome inhibitors.
Kazi A; Wang Z; Kumar N; Falsetti SC; Chan TH; Dou QP
Anticancer Res; 2004; 24(2B):943-54. PubMed ID: 15161048
[TBL] [Abstract][Full Text] [Related]
44. Structure-activity study of epi-gallocatechin gallate (EGCG) analogs as proteasome inhibitors.
Wan SB; Landis-Piwowar KR; Kuhn DJ; Chen D; Dou QP; Chan TH
Bioorg Med Chem; 2005 Mar; 13(6):2177-85. PubMed ID: 15727870
[TBL] [Abstract][Full Text] [Related]
45. A novel approach of proteomics and transcriptomics to study the mechanism of action of the antioxidant-iron chelator green tea polyphenol (-)-epigallocatechin-3-gallate.
Weinreb O; Amit T; Youdim MB
Free Radic Biol Med; 2007 Aug; 43(4):546-56. PubMed ID: 17640565
[TBL] [Abstract][Full Text] [Related]
46. Role of green tea polyphenols in the inhibition of collagenolytic activity by collagenase.
Madhan B; Krishnamoorthy G; Rao JR; Nair BU
Int J Biol Macromol; 2007 Jun; 41(1):16-22. PubMed ID: 17207851
[TBL] [Abstract][Full Text] [Related]
47. In vitro electrocardiographic and cardiac ion channel effects of (-)-epigallocatechin-3-gallate, the main catechin of green tea.
Kang J; Cheng H; Ji J; Incardona J; Rampe D
J Pharmacol Exp Ther; 2010 Aug; 334(2):619-26. PubMed ID: 20484151
[TBL] [Abstract][Full Text] [Related]
48. A broad spectrum anti-HIV inhibitor significantly disturbs V1/V2 domain rearrangements of HIV-1 gp120 and inhibits virus entry.
Berinyuy E; Soliman ME
J Recept Signal Transduct Res; 2016; 36(2):119-29. PubMed ID: 26446906
[TBL] [Abstract][Full Text] [Related]
49. In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4.
Andrianov AM; Nikolaev GI; Kornoushenko YV; Xu W; Jiang S; Tuzikov AV
Viruses; 2019 Aug; 11(8):. PubMed ID: 31412617
[TBL] [Abstract][Full Text] [Related]
50. Are blockers of gp120/CD4 interaction effective inhibitors of HIV-1 immunopathogenesis?
Herbeuval JP; Shearer GM
AIDS Rev; 2006; 8(1):3-8. PubMed ID: 16736946
[TBL] [Abstract][Full Text] [Related]
51. Structural analysis of catechin derivatives as mammalian DNA polymerase inhibitors.
Mizushina Y; Saito A; Tanaka A; Nakajima N; Kuriyama I; Takemura M; Takeuchi T; Sugawara F; Yoshida H
Biochem Biophys Res Commun; 2005 Jul; 333(1):101-9. PubMed ID: 15950188
[TBL] [Abstract][Full Text] [Related]
52. Antiplatelet activity of epigallocatechin gallate is mediated by the inhibition of PLCgamma2 phosphorylation, elevation of PGD2 production, and maintaining calcium-ATPase activity.
Jin YR; Im JH; Park ES; Cho MR; Han XH; Lee JJ; Lim Y; Kim TJ; Yun YP
J Cardiovasc Pharmacol; 2008 Jan; 51(1):45-54. PubMed ID: 18209568
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of HIV-1 envelope-mediated fusion by synthetic batzelladine analogues.
Bewley CA; Ray S; Cohen F; Collins SK; Overman LE
J Nat Prod; 2004 Aug; 67(8):1319-24. PubMed ID: 15332849
[TBL] [Abstract][Full Text] [Related]
54. Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1).
Yamaguchi K; Honda M; Ikigai H; Hara Y; Shimamura T
Antiviral Res; 2002 Jan; 53(1):19-34. PubMed ID: 11684313
[TBL] [Abstract][Full Text] [Related]
55. Click chemistry on azidoproline: high-affinity dual antagonist for HIV-1 envelope glycoprotein gp120.
Gopi HN; Tirupula KC; Baxter S; Ajith S; Chaiken IM
ChemMedChem; 2006 Jan; 1(1):54-7. PubMed ID: 16892335
[No Abstract] [Full Text] [Related]
56. Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.
Courter JR; Madani N; Sodroski J; Schön A; Freire E; Kwong PD; Hendrickson WA; Chaiken IM; LaLonde JM; Smith AB
Acc Chem Res; 2014 Apr; 47(4):1228-37. PubMed ID: 24502450
[TBL] [Abstract][Full Text] [Related]
57. Catechins containing a galloyl moiety as potential anti-HIV-1 compounds.
Zhao Y; Jiang F; Liu P; Chen W; Yi K
Drug Discov Today; 2012 Jun; 17(11-12):630-5. PubMed ID: 22414543
[TBL] [Abstract][Full Text] [Related]
58. Critical role of Arg59 in the high-affinity gp120-binding region of CD4 for human immunodeficiency virus type 1 infection.
Fontenot D; Jones JK; Hossain MM; Nehete PN; Vela EM; Dwyer VA; Jagannadha Sastry K
Virology; 2007 Jun; 363(1):69-78. PubMed ID: 17320923
[TBL] [Abstract][Full Text] [Related]
59. In Vitro and In Silico Studies of the Molecular Interactions of Epigallocatechin-3-
Saeki K; Hayakawa S; Nakano S; Ito S; Oishi Y; Suzuki Y; Isemura M
Molecules; 2018 May; 23(6):. PubMed ID: 29843451
[TBL] [Abstract][Full Text] [Related]
60. Peptides derived from HIV-1 gp120 co-receptor binding domain form amyloid fibrils and enhance HIV-1 infection.
Tan S; Li L; Lu L; Pan C; Lu H; Oksov Y; Tang X; Jiang S; Liu S
FEBS Lett; 2014 May; 588(9):1515-22. PubMed ID: 24657436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
